Table 1 (abstract A48).

Safety Summary

	2 years of abatacept treatment				6-month follow-up period
	Day 113	Day 477	Day 645	Day 729	Day 85	Day 168
2–5-year-old cohort
Anti-GAD+	1	1	0	0	0	0
Anti-TPO+	0	0	0	0	0	0
6–17-year-old cohort
Anti-GAD+	0	0	0	1‡	0	0
Anti-TPO+†	0	3	1	1‡	0	1

Values in table are number of patients. *Autoantibody positivity was defined as anti-GAD ≥5 IU/mL or anti-TPO ≥60 U/mL. TSH abnormalities were defined as >1.5x ULN, or if baseline was >ULN then >2x baseline value. †One patient had new-onset positive anti-TPO antibodies on Days 477, 645, 729 and Day 168 during the follow-up period. ‡The patients with positive anti-GAD and anti-TPO at Day 729 are different patients. GAD=glutamic acid decarboxylase; TPO=thyroid peroxidase; TSH=thyroid-stimulating hormone; ULN=upper limit of normal